Prophylactic antibiotics for the prevention of cellulitis

delayed breast cellulitis, recurrent cellulitis, recurrent erysipelas, soft tissue infections, Dermatolymphangioadenitis (DLA), Flesh Eating Bacteria, Bacterial Infections, Strep Infections, bacterial cellulitis, prophylactic antibiotics

Moderators: Birdwatcher, jenjay, patoco, Senior Moderators

Prophylactic antibiotics for the prevention of cellulitis

Postby patoco » Sat Sep 17, 2011 10:35 am

Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg - results of the UK Dermatology Clinical Trials Network's PATCH II trial.

Br J Dermatol. 2011 Sep 12.

Thomas KS; UK Dermatology Clinical Trials Network’s PATCH Trial Team.

Source

University of Nottingham, Centre of Evidence Based Dermatology.

Abstract

Background:  Cellulitis (erysipelas) of the leg is a common, painful infection of the skin and underlying tissue. Repeat episodes are frequent, cause significant morbidity and result in high health service costs.

Objectives: To assess whether prophylactic antibiotics prescribed after an episode of cellulitis of the leg can prevent further episodes. Methods:  Double-blind, RCT including patients recently treated for an episode of leg cellulitis. Recruitment took place in 20 hospitals. Randomisation was by computer generated code, and treatments allocated by post from a central pharmacy. Participants were enrolled for a maximum of 3 years and received their randomised treatment for the first 6 months of this period.

Results:  123 participants were randomised (31% of target due to slow recruitment). The majority (79%) had suffered one episode of cellulitis on entry into the study. The primary outcome of time to recurrence of cellulitis included all randomised participants and was blinded to treatment allocation. The hazard ratio showed that treatment with penicillin reduced the risk of recurrence by 47% (HR 0.53, 95% CI 0.26 to 1.07, p = 0.08). In the penicillin V group 12/60 (20%) had a repeat episode compared with 21/63 (33%) in the placebo group. This equates to a number needed to treat (NNT) of eight participants in order to prevent one repeat episode of cellulitis (95% CI NNT(harm) 48 to ∞ to NNT(benefit) 3. We found no difference between the two groups in the number of participants with oedema, ulceration or related adverse events.

Conclusions:  Although this trial was limited by slow recruitment, and the result failed to achieve statistical significance, it provides the best evidence available to date for the prevention of recurrence of this debilitating condition.

2011 British Association of Dermatologists.

FULL TEXT AVAILABLE:

http://onlinelibrary.wiley.com/doi/10.1 ... x/abstract
User avatar
patoco
Site Admin
 
Posts: 2175
Joined: Thu Jun 08, 2006 9:07 pm

Return to Lymphedema Infections, Cellulitis, lymphangitis

Who is online

Users browsing this forum: No registered users and 3 guests


cron